FINDINGS REGARDING CYTOKINES
An impaired DND repair might be involved in the aetology of breast cancer (Published in 1986).
The first-degree relatives of cancer patients have an increased incidence of defective DNA repair (Published in 1987 & in 1988).
Chemo/radiotherapy influences the DNA repair of cancer patients negatively shortly after treatment and 3-5 years after the end of treatment, leading to an increased risk of a secondary tumour (Published in 1992).
IL-16 is involved in cancer diseases and correlates with the progression. The results indicate that there is an increase of Interleukin-16 in sera during tumour progression due to an alteration in the function of the immunocompetent cells (Published in 2001).
The simultaneous measurement of IL-6, sIL-6R and sgp130 in sera of tumour patients patients is an important factor and necessary in evaluating the biological effect of IL-6 in malignant diseases (Published in 2001).
The serum values of sgp130 in cancer patients are elevated in all tumour stages. There are a correlation between the values of sgp130 and sIL-6R in all tumour stages (Published in 2001).
There are a significant correlation between the serum values of sICAM-1 and sgp130 in cancer patients with progression (Published in 2005).
IL-6 downregulates the membrane expression of gp130 in three multiple myeloma cell lines (OPM-2, RPMI-8226, U-266), although the proliferation of the myeloma cells increases
(Published in 2003 & in 2006).
There are a relationship between the cytostatic (inhibition of proliferation) and the cytocidal (killing of cells) effects of substances in multiple myeloma cell lines: Firstly the proliferation of tumour cells is inhibited and then afterwards these cells die by apoptosis or necrosis (Published in 2006 & in 2008).
IL-6 has a more marked effect on the proliferation of multiple myeloma cells with lower proliferation than on those with higher (Published in 2006).
Viscum album extract (VAQuFrF) inhibits the proliferation of several human multiple myeloma cell lines. The profile of its antitumour effect is identical to that of Vincristine
(Published in 2010)
Interleukin-6 leads to a marked production of Interleukin-10 in several human multiple myeloma cell lines. Interleukin-10 is an Interleukin-6 related growth factor for multiple myeloma cells. (Published in 2010).
European Patent Grant: Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases: EP 2464666 (Published in 2018).